by Truveta staff | May 29, 2025 | Data
Each year, more than 34,000 men in the U.S. die from prostate cancer. While early-stage disease is often highly treatable, outcomes still vary widely — especially by race, income, and geography. Catching the disease early can save lives, but real-world data on...
by Truveta staff | May 15, 2025 | Data
Cancer is one of the most heavily funded areas of medical research. And yet, with thousands of therapies in development and billions of dollars spent each year, many foundational questions persist: Why do patients stop treatment? How do outcomes vary across...
by Truveta staff | Apr 21, 2025 | Data
Asthma is one of the most studied chronic diseases in medicine, yet decades into the biologics era, researchers face familiar frustrations. Limited phenotyping, unpredictable treatment responses, persistent health disparities, and slow insight cycles can’t meet...
by Truveta staff | Mar 20, 2025 | Data
Why autoimmune research needs better real-world data Biologics like Humira, Enbrel, and Rinvoq have transformed autoimmune treatment, revolutionizing treatment for patients with chronic inflammatory infections. However, the traditional methods of studying these...
by Truveta staff | Feb 19, 2025 | Data
The need for better cardiovascular device insights Medical device companies are at the forefront of innovation, but a lack of real-world clinical data (RWD) hampers progress in studying cardiovascular device performance. Traditional data sources, such as claims and...
by Truveta News | Feb 13, 2025 | Data
Truveta Data has now expanded to include new commercial, Medicare, and Medicaid closed claims on more than 200 million patients, linked with electronic health record (EHR) data for more than 120 million patients already part of Truveta Data. Truveta Data now provides...
